Known targets — ChEMBL curated mechanism
KCNA5KCND3KCNH2KCNJ3KCNJ5SCN5A
The experimentally established mechanism targets of Vernakalant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 known ✓ | P22460 | 6/20 | 0.98 |
| ▸ | SCN5A known ✓ | Q14524 | 6/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | KCND2 | Q9NZV8 | 5/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vernakalant SCHEMBL409715 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL411264 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL670358 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL4602010 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL12375883 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL410062 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL10266911 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL13204358 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL9921603 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL12296079 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977373-B2 | Prodrugs of ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2011-07-12 | — | — | US | claimed |
| US-20090105256-A1 | PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2009-04-23 | — | — | US | claimed |
| JP-2007531766-A | — | — | 2007-11-08 | — | — | JP | claimed |
| US-20070197632-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP (CA) | 2007-08-23 | — | — | US | claimed |
| EP-1729815-A2 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | Cardiome Pharma Corp. (CA) | 2006-12-13 | — | — | EP | claimed |
| EP-1560812-B1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2006-05-10 | — | — | EP | claimed |
| WO-2005113011-A2 | PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2005-12-01 | — | — | WO | claimed |
| US-9586899-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2017-03-07 | — | — | US | disclosed |
| US-9586899-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2017-03-07 | — | — | US | disclosed |
| US-9586899-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2017-03-07 | — | — | US | disclosed |
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20150336887-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | CORREVIO CANADA CORP. (CA) | 2015-11-26 | — | — | US | disclosed |
| WO-2005094897-A2 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2005-10-13 | — | — | WO | disclosed |
| EP-1560812-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | Cardiome Pharma Corp. (CA) | 2005-08-10 | — | — | EP | disclosed |
| US-20050119315-A1 | Ion channel modulating activity II | CARDIOME PHARMA CORP. (CA) | 2005-06-02 | — | — | US | disclosed |
| US-20050070552-A1 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2005-03-31 | — | — | US | disclosed |
| US-20050038256-A1 | Synthetic process for trans-aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2005-02-17 | — | — | US | disclosed |
| US-20050026993-A1 | Uses of ion channel modulating compounds | CORREVIO CANADA CORP. (CA) | 2005-02-03 | — | — | US | disclosed |
| WO-2004099137-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119315-A1 | Ion channel modulating activity II | KCNH1, KCNN3, KCNJ2 | KCNA5 34/4885SCN5A 64/4885KCNH2 11/4885 |
| US-20050070552-A1 | Ion channel modulating activity I | KCNN1, KCNN3, KCNH1 | KCNA5 45/4885SCN5A 71/4885KCNH2 13/4885 |
| US-20090105256-A1 | PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CACNA1B, CACNA1F, KCNN2 | KCNA5 48/4885SCN5A 37/4885KCNH2 32/4885 |
| US-20070197632-A1 | Aminocyclohexyl ether compounds and uses thereof | KCNH2, KCNC1, KCNH3 | KCNA5 16/4885SCN5A 24/4885KCNH2 1/4885 |
| US-20050038256-A1 | Synthetic process for trans-aminocyclohexyl ether compounds | AKR1C3, CBR1, CBR3 | KCNA5 3636/4885SCN5A 3138/4885KCNH2 1685/4885 |
| US-20150336887-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | DDC, PAICS, CYP4F2 | KCNA5 3600/4885SCN5A 3852/4885KCNH2 1977/4885 |
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885KCNH2 8/4885 |
| US-20050026993-A1 | Uses of ion channel modulating compounds | KCNN1, KCNN2, KCNN3 | KCNA5 48/4885SCN5A 49/4885KCNH2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.